Cinitapride

Summary

Cinitapride (CHEMBL2104523) is a phase-3 clinical-stage small molecule (ATC A03FA08); indicated across 2 conditions including dyspepsia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A03FA08
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 402.5 Da · C21H30N4O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104523
Name	Cinitapride
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	68867
ATC	A03FA08
Molecular formula	C21H30N4O4
Molecular weight	402.5
InChIKey	ZDLBNXXKDMLZMF-UHFFFAOYSA-N

SMILES: CCOC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3CCC=CC3)[N+](=O)[O-])N

IUPAC name: 4-amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide

Also known as: Cinitaprida, Cinitapride, Paxapride, CINITAPRIDE, cinitapride

Patent coverage: 288 distinct patent families (980 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 967 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 20 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Neuronal acetylcholine receptor subunit alpha-4, 5-hydroxytryptamine receptor 3A, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Beta-2 adrenergic receptor, Muscarinic acetylcholine receptor M1, D(2) dopamine receptor, Motilin receptor, Sodium-dependent noradrenaline transporter.

Bioactivity

ChEMBL activities: 12 potent at pChembl ≥ 5 of 22 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR2B	8.64	AC50	2.3	nM	CHEMBL_ACT_25164019
HTR2A	8.05	AC50	9	nM	CHEMBL_ACT_25173494
DRD2	7.42	AC50	38	nM	CHEMBL_ACT_25139992
DRD3	7.42	AC50	38	nM	CHEMBL_ACT_25193194
HTR2A	7.16	AC50	70	nM	CHEMBL_ACT_25224862
HTR2B	6.72	AC50	190	nM	CHEMBL_ACT_25227208
KCNH2	6.51	AC50	310	nM	CHEMBL_ACT_25117355
ADRA2C	5.89	AC50	1300	nM	CHEMBL_ACT_25147535
HRH3	5.23	AC50	5900	nM	CHEMBL_ACT_25200315
MLNR	5.09	AC50	8100	nM	CHEMBL_ACT_25188860
OPRK1	5.04	AC50	9100	nM	CHEMBL_ACT_25129123
ADRA2B	5.03	AC50	9300	nM	CHEMBL_ACT_25143370

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
dyspepsia	3	MONDO:0002268	EFO:0008533

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01355276	PHASE3	COMPLETED	Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).